Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer
- PMID: 15245814
- DOI: 10.1016/j.eururo.2004.04.008
Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer
Abstract
Introduction and objectives: Hypoxia-inducible factor 1 alpha (HIF-1 alpha) is a critical regulatory protein of cellular response to hypoxia and is closely related to the triggering of the angiogenic process. We examined the relationship between hypoxia and angiogenesis, as well as their prognostic impact in patients with urothelial bladder cancer.
Methods: The immunohistochemical expression of HIF-1 alpha was evaluated in 93 formalin-fixed paraffin-embedded primary transitional cell carcinoma tissue samples. HIF-1 alpha was recognized through nuclear staining of positive cells. The angiogenic profile was individually assessed immunohistochemically using a monoclonal antibody to vascular endothelial growth factor (VEGF) and microvessel density (MVD) was calculated with immunohistochemical staining of the adhesion molecule CD31 of the endothelial cells.
Results: A significant positive association between HIF-1 alpha immunoreactivity and histological grade (p=0.009) was found. VEGF and MVD were closely related to tumor grade (p=0.06 and p<0.001) and clinical stage (p=0.04 and p<0.01, respectively). HIF-1 alpha was significantly correlated with VEGF expression (p=0.01) and MVD (p<0.001). Patients characterized by HIF-1 alpha overexpression had significantly worse overall (p=0.009) and disease-free survival (p=0.03). When HIF-1 alpha, histologic grade and stage were included in multivariate Cox regression analysis, HIF-1 alpha emerged as an independent prognostic factor (p=0.02) along with grade and stage, but lost its independent prognostic value after the inclusion of angiogenic factors in the multivariate model. In the subgroup of patients with T1 disease, HIF-1 alpha emerged as a significant negative predictor of the time to first recurrence.
Conclusions: HIF-1 alpha and angiogenesis markers may play an important predictive and prognostic role in patients with bladder cancer. HIF-1 alpha may be of biologic and clinical value as its overexpression is related to up-regulation of VEGF, the stimulation of angiogenesis and worse prognosis.
Similar articles
-
Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.J Clin Pathol. 2008 May;61(5):658-64. doi: 10.1136/jcp.2007.050666. Epub 2007 Oct 1. J Clin Pathol. 2008. PMID: 17908805
-
Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.BJU Int. 2005 Feb;95(3):425-31. doi: 10.1111/j.1464-410X.2005.05314.x. BJU Int. 2005. PMID: 15679808
-
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.Cancer. 2002 Sep 1;95(5):1055-63. doi: 10.1002/cncr.10774. Cancer. 2002. PMID: 12209691
-
Angiogenesis, angiogenic factor expression and prognosis of bladder cancer.Anticancer Res. 2001 Nov-Dec;21(6B):4355-63. Anticancer Res. 2001. PMID: 11908691 Review.
-
Hypoxia-inducible factor 1 (HIF-1) in cancer.Eur J Surg Oncol. 2004 Jun;30(5):465-8. doi: 10.1016/j.ejso.2004.03.008. Eur J Surg Oncol. 2004. PMID: 15135470 Review.
Cited by
-
Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma.Gastric Cancer. 2006;9(1):44-9. doi: 10.1007/s10120-005-0356-1. Gastric Cancer. 2006. PMID: 16557436
-
HIF1α: A Novel Biomarker with Potential Prognostic and Immunotherapy in Pan-cancer.Oxid Med Cell Longev. 2022 Jul 8;2022:1246267. doi: 10.1155/2022/1246267. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35860430 Free PMC article.
-
Positive correlation between the expression of hEag1 and HIF-1α in breast cancers: an observational study.BMJ Open. 2014 May 16;4(5):e005049. doi: 10.1136/bmjopen-2014-005049. BMJ Open. 2014. PMID: 24838727 Free PMC article.
-
Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.Med Oncol. 2017 Dec 4;35(1):3. doi: 10.1007/s12032-017-1067-2. Med Oncol. 2017. PMID: 29209984
-
Preliminary Analysis of the Expression of Selected Proangiogenic and Antioxidant Genes and MicroRNAs in Patients with Non-Muscle-Invasive Bladder Cancer.J Clin Med. 2016 Feb 25;5(3):29. doi: 10.3390/jcm5030029. J Clin Med. 2016. PMID: 26927195 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical